VOLUME 11 NUMBER 2 • JUNE 2014
93
SA JOURNAL OF DIABETES & VASCULAR DISEASE
REVIEW
52. Sartor G, Dahlquist G. Short-term mortality in childhood onset insulin-dependent
diabetes mellitus: a high frequency of unexpected deaths in bed.
Diabet Med
1995;
12
: 607–611.
53. Dahlquist G, Kallen B: Mortality in childhood-onset type 1 diabetes: a population-
based study.
Diabetes Care
2005;
28
: 2384–2387.
54. Skrivarhaug T, Bangstad HJ, Stene LC,
et al
. Long-term mortality in a nationwide
cohort of childhood-onset type 1 diabetic patients in Norway.
Diabetologia
2006,
49
: 298–305.
55. Tu E, Twigg SM, Duflou J, Semsarian C. Causes of death in young Australians
with type 1 diabetes: a review of coronial postmortem examinations.
Med J Aust
2008;
188
: 699–702.
56. Barkai L, Gurieva I, Stirban A,
et al.
Microvascular complications in children and
adolescents with type 1 diabetes.
Diabetes Metab Heart
2012;
21
: 309–315.
57. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and
cardiovascular disease in patients with type 1 diabetes.
N Engl J Med
2005;
353:
2643–2653.
58. Orchard TJ, Olson JC, Erbey JR,
et al
. Insulin resistance-related factors, but not
glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up
data from the Pittsburgh Epidemiology of Diabetes Complications Study.
Diabetes
Care
2003;
26
: 1374–1379.
59. The DCCT Research Group. The effect of intensive treatment of diabetes on the
development and progression of long-term complications in insulin-dependent
diabetes mellitus. The Diabetes Control and Complications Trial Research Group.
N Engl J Med
1993;
329
: 977–986.
60. Sustained effect of intensive treatment of type 1 diabetes mellitus on
development and progression of diabetic nephropathy: the Epidemiology of
Diabetes Interventions and Complications (EDIC) study
J Am Med Assoc
2003;
290
: 2159–2167.
61. Monti MC, Lonsdale JT, Montomoli C,
et al.
Familial risk factors for microvascular
complications and differential male–female risk in a large cohort of American
families with type 1 diabetes.
J Clin Endocrinol Metab
2007;
92
: 4650–4655.
62. Conway B, Costacou T, Orchard T. Is glycaemia or insulin dose the stronger risk
factor for coronary artery disease in type 1 diabetes?
Diab Vasc Dis Res
2009;
6
:
223–230.
63. Dorchy H, Claes C, Verougstraete C. Risk factors of developing proliferative
retinopathy in type 1 diabetic patients: role of BMI.
Diabetes Care
2002;
25
:
798–799.
64. De Block CE, De Leeuw IH, Van Gaal LF. Impact of overweight on chronic
microvascular complications in type 1 diabetic patients.
Diabetes Care
2005,
28
:1649-1655. Stone ML, Craig ME, Chan AK,
et al.
Natural history and risk
factors for microalbuminuria in adolescents with type 1 diabetes: a longitudinal
study.
Diabetes Care
2006;
29
: 2072–2077.
65. Tesfaye S, Stevens LK, Stephenson JM,
et al.
Prevalence of diabetic peripheral
neuropathy and its relation to glycaemic control and potential risk factors: the
EURODIAB IDDM Complications Study.
Diabetologia
1996;
39
: 1377–1384.
66. Chase HP, Garg SK, Marshall G,
et al
. Cigarette smoking increases the risk of
albuminuria among subjects with type I diabetes.
J Am Med Assoc
1991;
265:
614–617.
67. Mohamed Q, Gillies MC, Wong TY: Management of diabetic retinopathy: a
systematic review.
J Am Med Assoc
2007;
298
: 902–916.
68. Tuomilehto J, Borch-Johnsen K, Molarius A,
et al.
Incidence of cardiovascular
disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic
nephropathy in Finland.
Diabetologia
1998;
41
: 784–790.
69. Turkbey EB, Backlund JY, Genuth S,
et al
. Myocardial structure, function, and scar
in patients with type 1 diabetes mellitus.
Circulation
2011;
124
: 1737–1746.
70. Mancia G, Fagard R, Narkiewicz K,
et al.
2013 ESH/ESC Guidelines for the
management of arterial hypertension: The Task Force for the management of
arterial hypertension of the European Society of Hypertension (ESH) and of the
European Society of Cardiology (ESC).
Eur Heart J
2013. Epub ahead of print.
71. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in parents of proteinuric
insulin dependent diabetics.
Br Med J
(Clin Res Ed) 1987;
295
: 515–517.
72. Krolewski AS, Canessa M, Warram JH,
et al.
Predisposition to hypertension and
susceptibility to renal disease in insulin-dependent diabetes mellitus.
N Engl J
Med
1988;
318
: 140–145.
73. Lurbe E, Redon J, Kesani A,
et al
. Increase in nocturnal blood pressure and
progression to microalbuminuria in type 1 diabetes.
N Engl J Med
2002;
347
:
797–805.
74. de Boer IH, Kestenbaum B, Rue TC,
et al.
Insulin therapy, hyperglycemia, and
hypertension in type 1 diabetes mellitus.
Arch Intern Med
2008;
168
: 1867–1873.
75. Giuffrida FM, Guedes AD, Rocco ER,
et al.
Heterogeneous behavior of lipids
according to HbA
1c
levels undermines the plausibility of metabolic syndrome in
type 1 diabetes: data from a nationwide multicenter survey.
Cardiovasc Diabetol
2012;
11
: 156.
76. Prince CT, Secrest AM, Mackey RH,
et al.
Pulse wave analysis and prevalent
cardiovascular disease in type 1 diabetes.
Atherosclerosis
2010;
213
:469-474.
77. Turkbey EB, Redheuil A, Backlund JY,
et al
. Aortic Distensibility in type 1 diabetes.
Diabetes Care
2013. Epub ahead of print.
78. Genuth S, Backlund JY, Bayless M,
et al.
Effects of Prior Intensive versus
Conventional Therapy and History of Glycemia on Cardiac Function in Type 1
Diabetes in the DCCT/EDIC.
Diabetes
2013. Epub ahead of print.
79. Nathan DM, Lachin J, Cleary P,
et al
. Intensive diabetes therapy and carotid
intima-media thickness in type 1 diabetes mellitus.
N Engl J Med
2003;
348
:
2294–2303.
80. Olson JC, Edmundowicz D, Becker DJ, Kuller LH, Orchard TJ: Coronary calcium in
adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease
in men than in women.
Diabetes
2000;
49
: 1571–1578.
81. Snell-Bergeon JK, Hokanson JE, Jensen L,
et al.
Progression of coronary artery
calcification in type 1 diabetes: the importance of glycemic control.
Diabetes
Care
2003;
26
: 2923–2928.
82. Thilo C, Standl E, Knez A,
et al.
Coronary calcification in long-term type 1
diabetic patients – a study with multi slice spiral computed tomography.
Exp Clin
Endocrinol Diabetes
2004;
112
: 561–565.
83. Rathsman B, Rosfors S, Sjoholm A, Nystrom T. Early signs of atherosclerosis are
associated with insulin resistance in non-obese adolescent and young adults with
type 1 diabetes.
Cardiovasc Diabetol
2012;
11
: 145.
84. Dalla Pozza R, Beyerlein A, Thilmany C,
et al.
The effect of cardiovascular risk
factors on the longitudinal evolution of the carotid intima medial thickness in
children with type 1 diabetes mellitus.
Cardiovasc Diabetol
2011;
10
: 53.
85. Turek SJ, Hastings SM, Sun JK, King GL, Keenan HA. Sexual dysfunction as
a marker of cardiovascular disease in males with 50 or more years of type 1
diabetes.
Diabetes Care
2013;
36
(10): 3222–3226.
86. Pratte KA, Baron AE, Ogden LG,
et al.
Plasminogen activator inhibitor-1 is
associated with coronary artery calcium in Type 1 diabetes.
J Diabetes Complicat
2009;
23
: 387–393.
87. Bosnyak Z, Forrest KY, Maser RE, Becker D, Orchard TJ. Do plasminogen activator
inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict
complications in Type 1 diabetes: the Pittsburgh Epidemiology of Diabetes
Complications Study.
Diabet Med
2003;
20
: 147–151.
88. American Diabetes Association (ADA). Standards of medical care in diabetes –
2013.
Diabetes Care
2013;
36
: S11–S66.
89. Donaghue KC, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K. Microvascular
and macrovascular complications associated with diabetes in children and
adolescents.
Pediatr Diabetes
2009;
10
(Suppl 12): 195–203.
90. Tesfaye S, Boulton AJ, Dyck PJ,
et al.
Diabetic neuropathies: update on definitions,
diagnostic criteria, estimation of severity, and treatments.
Diabetes Care
2010;
33
: 2285–2293.
91. Geluk CA, Dikkers R, Kors JA,
et al
. Measurement of coronary calcium scores or
exercise testing as initial screening tool in asymptomatic subjects with ST-T changes
on the resting ECG: an evaluation study.
BMC Cardiovasc Disord
2007;
7
: 19.
92. Budoff MJ, Gul KM: Expert review on coronary calcium.
Vasc Health Risk Manag
2008;
4
: 315–324.
93. Donaghue KC, Fairchild JM, Craig ME,
et al
. Do all prepubertal years of diabetes
duration contribute equally to diabetes complications?
Diabetes Care
2003;
26
:
1224–1229.
94. Effect of intensive diabetes treatment on the development and progression of
long-term complications in adolescents with insulin-dependent diabetes mellitus:
Diabetes Control and Complications Trial. Diabetes Control and Complications
Trial Research Group.
J Pediatr
1994;
125
: 177–188.
95. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control
with sulphonylureas or insulin compared with conventional treatment and risk
of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective
Diabetes Study (UKPDS) Group.
Lancet
1998;
352
: 837–853.
96. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto
Study on optimal diabetes control in type 2 diabetic patients.
Diabetes Care
2000;
23
(Suppl 2): B21–B29.
97. Retinopathy and nephropathy in patients with type 1 diabetes four years after
a trial of intensive therapy. The Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications Research Group. N
Engl J Med
2000;
342
: 381–389.
98. Salardi S, Balsamo C, Zucchini S,
et al
. High rate of regression from micro-
macroalbuminuria to normoalbuminuria in children and adolescents with type 1
diabetes treated or not with enalapril: the influence of HDL cholesterol.
Diabetes
Care
2011;
34
: 424–429.
99. Amin R, Widmer B, Prevost AT,
et al.
Risk of microalbuminuria and progression to
macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective
observational study.
Br Med J
2008;
336
: 697–701.
